Skandinaviska Enskilda Banken (SEB)
PCVX icon

Skandinaviska Enskilda Banken (SEB)’s Vaxcyte PCVX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,350
Closed -$353K – 875
2025
Q1 		$353K Buy
+9,350
New +$748K ﹤0.01% 718

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s PCVX Position: Q2 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 9,350 shares — an estimated $353K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in PCVX in Q1 2025 and held it in 1 quarter. The position peaked at $353K in Q1 2025. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 9,350 Vaxcyte shares in Q2 2025, an estimated $353K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Vaxcyte in Q1 2025 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Vaxcyte position peaked at $353K in Q1 2025.
  • 294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q2 2025, filed 13 Aug 2025.